Background
Methods
Protocol and registration
Eligibility criteria
Search strategy
Study selection
Data extraction
Categorizing similar outcomes
Assignment of outcome category to core areas
Results
First author (ref.) | Year | Intervention type | Intervention | Study type | Region of origin | Sample Size |
---|---|---|---|---|---|---|
Ebner [29] | 2007 | P | Morphine | PCS | Austria | 53 |
Abrahams [30] | 2007 | NP | Rooming-in | RCS | Canada | 106 |
Mazurier [31] | 2008 | P | Morphine | CS | France | 37 |
Colombini [32] | 2008 | P | Morphine | PCS | France | 22 |
Jansson [33] | 2008 | NP | Breast feeding | PCS | USA | 16 |
Kraft [34] | 2008 | P | Sublingual buprenorphine | RCT | USA | 26 |
Agthe [35] | 2009 | P | Clonidine | RCT | USA | 80 |
Leikin [36] | 2009 | P | Clonidine | CS | USA | 14 |
Abrahams [37] | 2010 | NP | Rooming-in | RCS | Canada | 952 |
Saiki [38] | 2010 | NP | Postnatal ward | RCS | UK | 60 |
Esmaeili [39] | 2010 | P | Clonidine and chloral hydrate | RCS | Germany | 133 |
O’Mara [40] | 2010 | P | Clonidine | CR | USA | 1 |
Isemann [41] | 2011 | NP | Breastfeeding | RCS | USA | 128 |
Kraft [42] | 2011 | P | Sublingual buprenorphine | RCT | USA | 24 |
McQueen [43] | 2011 | NP | Breastfeeding | RCS | Canada | 28 |
Schwartz [44] | 2011 | NP | Auricular acupressure | RCT | USA | 76 |
Backes [45] | 2012 | NP | Outpatient weaning | RCS | USA | 121 |
Filippelli [46] | 2012 | NP | Noninsertive acupuncture | CS | USA | 54 |
Murphy-Oikonen [47] | 2012 | NP | Clinical practice guideline | RCS | Canada | 90 |
O’Connor [48] | 2013 | NP | Breastfeeding | RCS | USA | 85 |
Welle-Strand [49] | 2013 | NP | Breastfeeding | Mixed method (RCS and PCS) | Norway | 124 |
Surran [50] | 2013 | P | Clonidine adjunct | RCT | USA | 68 |
Hall [51] | 2014 | P | Weaning protocols for morphine, methadone, buprenorphine | RCS | USA | 547 |
Bhatt-Mehta [52] | 2014 | P | Methadone | RCS | USA | 60 |
Smirk [53] | 2014 | NP | Home-based detoxification | RCS | Australia | 118 |
Asti [54] | 2015 | NP | Implementation of standardized protocol | QI | USA | 92 |
Hall [55] | 2015 | P | Methadone weaning protocol | PCS | USA | 360 |
Liu [56] | 2015 | NP | Breastfeeding | RCS | Australia | 194 |
Hall [57] | 2015 | P | Standardized weaning protocol | RCS | USA | 981 |
Raith [58] | 2015 | NP | Laser acupuncture | RCT | Austria | 28 |
Brown [59] | 2015 | P | Methadone | RCT | USA | 31 |
Bada [60] | 2015 | P | Morphine | RCT | USA | 31 |
Lee [61] | 2015 | NP | Combined in/outpatient | RCS | USA | 139 |
Nayeri [62] | 2015 | P | Phenobarbital | RCT | Iran | 60 |
Young [63] | 2015 | P | Oral morphine | RCS | USA | 26 |
Newman [64] | 2015 | NP | Rooming-in | PCS | Canada | 45 |
Kelly [65] | 2015 | NP | Home weaning | RCS | Canada | 80 |
Hall [66] | 2016 | P | Buprenorphine | RCS | USA | 201 |
Ibach [67] | 2016 | P | Methadone | RCS | USA | 50 |
Hahn [68] | 2016 | NP | Massage | Qualitative thematic analysis | USA | 8 |
Holmes [69] | 2016 | NP | Rooming-in | QI | USA | 163 |
Short [70] | 2016 | NP | Breastfeeding | RCS | USA | 3725 |
Patrick [71] | 2016 | NP | Evidence-based practice guidelines | QI | USA | 3458 |
Kraft [72] | 2017 | P | Buprenorphine | RCT | USA | 63 |
Zuzarte [73] | 2017 | NP | Vibrotactile stimulation | Prospective within-subject study | USA | 26 |
Grossman [74] | 2017 | NP | Standardization and inpatient unit | QI | USA | 287 |
Howard [75] | 2017 | NP | Parental presence | RCS | USA | 86 |
Description of outcomes reported in primary research studies
Outcome | Reported outcome definition |
---|---|
Duration of pharmacotherapy (n = 32) | Days of opioid treatment |
Duration of treatment for NAS symptoms | |
Duration of pharmacotherapy for NAS/NOWS | |
Days of treatment | |
Duration of treatment required for NAS resolution | |
Number of days on morphine | |
Duration of opioid treatment | |
Duration of oral morphine treatment | |
Length of opioid treatment | |
Length of methadone therapy | |
Duration of phenobarbital treatment | |
Total phenobarbital treatment days | |
Total treatment duration (hospital + home) | |
Length of treatment | |
Days on DTO | |
Days on any form of pharmacologic support | |
Duration of hospital stay (n = 31) | Days of inpatient hospitalization |
Neonatal length of stay | |
Length of inpatient stay | |
Duration of hospital stay | |
Mean infant hospital stay | |
Average length of stay between hospitals | |
NICU level of care (n = 8) | NICU admission |
Length of NICU stay | |
Admission to level II nursery or chronic care unit | |
Adverse event—unplanned ICU transfer | |
Transferred to NICU from inpatient unit | |
Breastfeeding or human milk nutrition (n = 12) | Breastfeeding during hospital stay |
Breastfeeding at discharge | |
Initiation of breastfeeding | |
Breastfeeding rates 6–8 weeks of age | |
Rate of breastfeeding | |
Duration of breast feeding | |
Breastfeeding | |
Taking ≥50% of feed as breast milk at discharge | |
Discharge on human milk | |
Opioid withdrawal symptoms (n = 24) | Neonatal substance withdrawal |
Withdrawal symptoms | |
Time of onset of symptoms | |
Severity of NAS/NOWS | |
Average daily score | |
Mean NAS score | |
Intensity of withdrawal | |
Control of withdrawal symptoms | |
Number of times NAS score >8 | |
Mean Finnegan withdrawal scores | |
Treatment effectiveness | |
Duration of neonatal abstinence syndrome | |
Severity of NAS (mean peak NAS) | |
NAS scores (undefined time point) | |
Highest Finnegan score | |
Time to highest Finnegan score | |
Highest NAS score | |
Prevalence of symptoms of NAS | |
Custody at discharge (n = 7) | Custody status at discharge |
Discharge of babies in the custody of their mothers | |
Child placed in foster care | |
Discharge in parental care | |
Discharge from hospital with their biological family | |
Dose of pharmacotherapy (n = 18) | Total dose (mg/kg) of methadone administered |
Range of morphine doses (mg/kg/day) | |
Morphine doses during the first 38 days of treatment | |
Maximum morphine dose (mean mg/kg/day) | |
Initial median opioid dose (methadone or morphine PO) | |
Cumulative morphine dose | |
Total opioid dose | |
Maximum clonidine dose | |
Highest mean methadone dose given | |
Amount of DTO required to treat NAS | |
Mean total morphine dose | |
Maximum amount of morphine (mL/kg) | |
Time to maximum amount of oral morphine | |
Median dosages over time | |
Average phenobarbital dose | |
Addition of adjunctive therapy (n = 17) | Phenobarbital adjunct therapy |
Percentage treated with an adjuvant medication | |
Adjunct medications | |
Addition of a second agent (clonidine or phenobarbital) | |
Amount of pharmacologic support | |
Addition of a second agent | |
Initiation of pharmacotherapy (n = 11) | Treated with morphine |
Pharmacologic treatment for NAS | |
Need for treatment of NAS | |
Need for pharmacotherapy with morphine | |
Percentage of cohort requiring oral morphine | |
Weight (n = 7) | Weight gain |
Discharge weight | |
Weight loss greater than 10% in the first week of life | |
Time to regain birthweight | |
Poor weight gain | |
Time to symptom control (n = 3) | Duration of treatment to achieve Lipsitz score below 4 |
Treatment response | |
Time to symptom control after initiation of therapy | |
Cost of treatment (n = 6) | Costs for all opioid-exposed infants |
Costs for all opioid-exposed infants treated pharmacologically | |
Average hospital cost per infant | |
Total cost of treatment | |
Average total cost of hospitalization (direct and indirect) | |
Cost-effectiveness | |
Development (n = 2) | Infant neurobehavior |
Neurobehavior | |
Adverse events (n = 14) | Safety of noninsertive acupuncture |
Neonatal safety (adverse drug reactions) | |
Safe | |
Safety (adverse events) | |
Seizures | |
Mortality in hospital | |
Infant death | |
Unintended side effects | |
Readmission to hospital (n = 9) | Return to hospital for withdrawal treatment |
Readmission to hospital | |
Readmission in 1 week postdischarge | |
Readmission in the first year of life | |
Hospital readmission 2 months following discharge | |
30-day readmissions (all cause) | |
30-day readmission (withdrawal) |
Type of study | First most commonly reported outcome category | Second most commonly reported outcome category(ies) | Third most commonly reported outcome category(ies) |
---|---|---|---|
Retrospective cohort study (n = 21) | Duration of hospital stay (16%) | NAS symptoms (13%) | Duration of pharmacotherapy (12%) |
Randomized controlled trial (n = 10) | Duration of pharmacotherapy (22%) | Duration of hospital stay (12%) | Adjunctive therapy (10%) |
Adverse events (10%) | |||
Prospective cohort study (n = 5) | Dose of pharmacotherapy (22%) | Duration of pharmacotherapy (17%) | Duration of hospital stay (11%) |
NAS symptoms (11%) | |||
Initiation of pharmacotherapy (11%) | |||
Quality improvement (n = 4) | Duration of hospital stay (15%) | Adverse events (12%) | Initiation of pharmacotherapy (8%) |
Cost of treatment (12%) | Readmission to hospital (8%) | ||
Advancing level of care (NICU admission) (12%) | Feeding breast milk (8%) | ||
Custody at discharge (8%) | |||
Case series and case report (n = 4) | Miscellaneous single outcomes (25%) | Duration of pharmacotherapy (17%) | Duration of hospital stay (8%) |
NAS symptoms (17%) | Dose of pharmacotherapy (8%) | ||
Adverse events (17%) | Adjunctive therapy (8%) | ||
Qualitative study (n = 1) | NAS symptoms (100%) | ||
Mixed method (n = 1) | Feeding breast milk (100%) | NAS symptoms (25%) | |
Initiation of pharmacotherapy (25%) | |||
Prospective within-subject study(n = 1) | Miscellaneous single outcomes (100%) |